HELPTAG: LFTE Nav Bar

Feb 17, 2014

Home | Communities | News in Brief | Vendor Connect | Education | Conferences | Forums | Links | Webinars
Latest in Home
Woman Mother Stressed 400
MRI shows how hormones affect mood
September 2, 2026
Cirse2025
What to watch for at CIRSE 2026
September 2, 2026
Prof. Ken Herrmann, director of the Department of Nuclear Medicine at University Hospital Essen, pictured fourth from the left, at the opening opening of a new nuclear medicine center in Essen, Germany, focused on theranostics and personalized cancer care.
Q&A with Ken Herrmann: Theranostics must move earlier and beyond established targets
September 1, 2026
Example of AI-assisted pulmonary nodule detection and longitudinal volumetric assessment in a 65-year-old woman with peripheral arterial disease, a 24-pack-year smoking history, emphysema, and a family history of lung cancer. An incidental 8.5-mm right lower lobe pulmonary nodule is identified at CT angiography of the abdomen in July 2022 but does not receive follow-up. Subsequent imaging demonstrates interval growth, and CT-guided biopsy confirms stage IA lung adenocarcinoma. Contrast-enhanced axial chest CT images obtained on February 2, 2024, before robotic-assisted thoracoscopic segmentectomy, show a 12.1-mm spiculated right lower lobe pulmonary nodule. (A) Conventional contrast-enhanced axial chest CT image without AI assistance shows a 12.1-mm spiculated right lower lobe pulmonary nodule. (B) Corresponding CT image with AI-assisted pulmonary nodule detection, automated segmentation, and quantitative nodule assessment identifies a solid pulmonary nodule (nodule #1) measuring 13 × 8 (11) mm, with a volume of 739 mm3, a 45% volumetric increase compared with the previous contrast-enhanced chest CT performed on October 9, 2023 (510 mm3), and an estimated volume doubling time (VDT) of 216 days. (C) AI-generated longitudinal nodule analysis displays automated segmentation of the current (February 2, 2024) and previous (October 9, 2023) CT examinations, 3D nodule reconstruction, and quantitative volumetric assessment for longitudinal follow-up. The AI interface is displayed in the original software language (Dutch).
AI cuts chest CT reporting time
September 1, 2026
More in Home
MRI shows how hormones affect mood
By Amerigo Allegretto
MRI scans show how higher progesterone levels indicate lower mood.
September 2, 2026
Woman Mother Stressed 400
What to watch for at CIRSE 2026
By Claudia Tschabuschnig
The program spans new treatments, clinical practice, training, and access to IR across Europe.
September 2, 2026
Cirse2025
Q&A with Ken Herrmann: Theranostics must move earlier and beyond established targets
By Claudia Tschabuschnig
Prof. Ken Herrmann discusses the expansion of radioligand therapy into earlier treatment lines, the need for new cancer targets, long-term safety, and the challenge of translating innovation into robust clinical evidence.
September 1, 2026
Prof. Ken Herrmann, director of the Department of Nuclear Medicine at University Hospital Essen, pictured fourth from the left, at the opening opening of a new nuclear medicine center in Essen, Germany, focused on theranostics and personalized cancer care.
AI cuts chest CT reporting time
By Will Morton
Exploratory modeling suggested an approximate reduction of 0.5 full-time equivalent radiologist workload.
September 1, 2026
Example of AI-assisted pulmonary nodule detection and longitudinal volumetric assessment in a 65-year-old woman with peripheral arterial disease, a 24-pack-year smoking history, emphysema, and a family history of lung cancer. An incidental 8.5-mm right lower lobe pulmonary nodule is identified at CT angiography of the abdomen in July 2022 but does not receive follow-up. Subsequent imaging demonstrates interval growth, and CT-guided biopsy confirms stage IA lung adenocarcinoma. Contrast-enhanced axial chest CT images obtained on February 2, 2024, before robotic-assisted thoracoscopic segmentectomy, show a 12.1-mm spiculated right lower lobe pulmonary nodule. (A) Conventional contrast-enhanced axial chest CT image without AI assistance shows a 12.1-mm spiculated right lower lobe pulmonary nodule. (B) Corresponding CT image with AI-assisted pulmonary nodule detection, automated segmentation, and quantitative nodule assessment identifies a solid pulmonary nodule (nodule #1) measuring 13 × 8 (11) mm, with a volume of 739 mm3, a 45% volumetric increase compared with the previous contrast-enhanced chest CT performed on October 9, 2023 (510 mm3), and an estimated volume doubling time (VDT) of 216 days. (C) AI-generated longitudinal nodule analysis displays automated segmentation of the current (February 2, 2024) and previous (October 9, 2023) CT examinations, 3D nodule reconstruction, and quantitative volumetric assessment for longitudinal follow-up. The AI interface is displayed in the original software language (Dutch).
Bayer's PET agent meets endpoints in phase III cardiac amyloidosis study
By Will Morton
Overall sensitivity was 94% (95% CI, 85% to 98%) and specificity was 86% (95% CI, 77% to 92%).
August 31, 2026
This figure shows fused I-124 evuzamitide positron emission tomography (PET)/computed tomography (CT) images from patients without amyloidosis and from patients with ATTR cardiac amyloidosis, early ATTR cardiac amyloidosis, light chain cardiac amyloidosis, gelsolin-mediated amyloidosis, and systemic organ amyloid. The columns represent radiological transaxial, sagittal, and coronal views except for the last row middle and far right columns, which are coronal projections. The blue asterisks represent physiological activity (tracer activity in the stomach and esophagus). The arrowheads represent pathological uptake. Note the small amount of cardiac uptake in the basal septum and the basal lateral walls (likely early ATTR cardiac amyloidosis), splenic uptake and pleural uptake in light chain amyloidosis, and cardiac and kidney uptake in gelsolin-mediated amyloidosis. The bright yellow color represents more tracer uptake.
Video: Ken Herrmann maps nuclear medicine’s next frontiers
By Claudia Tschabuschnig
From earlier PSMA-targeted therapy and new cancer targets to total-body PET and low-dose screening, Prof. Ken Herrmann outlines where nuclear medicine could go next.
August 31, 2026
Ken Herrman1
SPECT, PET refine contemporary cardiac amyloidosis assessment
By Claudia Tschabuschnig
Experts highlighted SPECT/SPECT-CT as central to reliable cardiac amyloidosis imaging, while emerging PET tracers may improve early detection, disease characterization, and follow-up.
August 24, 2026
Shutterstock 2437656775
Advanced ultrasound techniques improve soft tissue tumor evaluation
By Amerigo Allegretto
Both SWE and SMI can help distinguish benign from malignant soft tissue tumors.
August 26, 2026
Examples of ultrasound findings and techniques. (A) Images in a 39-year-old male patient with a mass in the left thigh. The mass is heterogeneous on the B-mode US image (compared with the patient in D) and showed increased microvascularity (superb microvascular imaging [SMI]) and shear-wave elastography (SWE) values. Undifferentiated pleomorphic sarcoma was diagnosed at biopsy (with pleomorphic rhabdomyosarcoma in surgical specimen). (B) Images in an 18-year-old male patient with a mass in the left leg. The mass is hypoechoic on the B-mode image, with no other findings suggestive of malignancy. The lesion is in contact with the cortex of the tibia, which is slightly irregular. CT revealed a doubtful anteromedial tibial erosion. The microvascular study demonstrated high vascularization, suggestive of malignancy. Periosteal Ewing sarcoma was diagnosed with both histologic and immunohistochemical confirmation. (C) Images in a 69-year-old female patient with a lump growing on the outside of the left leg. Multiple SWE examinations were performed (please note the high values obtained in the measurements, whereas the color map highlights the stiffness relative to adjacent tissues). SMI showed areas of increased vascularization to target for sampling. Undifferentiated spindle cell sarcoma was diagnosed at biopsy, with residual leiomyosarcoma in the surgical specimen after neoadjuvant therapy. (D) Images in a 56-year-old female patient with a mass in the right thigh. The mass is heterogeneous at both B-mode ultrasound (similar to patient A) and MRI (coronal T2-weighted spectral attenuated inversion recovery [SPAIR]; T1-weighted pre-contrast and postcontrast imaging), which even shows uptake after the administration of paramagnetic contrast material, which is traditionally suggestive of malignancy. Low values at SMI and elastography are suggestive of benignity. Spindle cell lipoma was diagnosed at biopsy, with atypical spindle cell lipomatous tumor in the surgical specimen.
Swiss nuclear medicine seeks rules fit for radiopharmaceutical innovation
By Claudia Tschabuschnig
Funding, advanced technology, and the country’s small scale help make Switzerland an innovative environment for nuclear medicine.
August 27, 2026
Antoine Leimgruber
Leimgruber: Nuclear medicine needs regulation fit for innovation
By Claudia Tschabuschnig
In a video interview, Dr. Antoine Leimgruber, director ofdevelopment for nuclear medicine at Swiss Medical Network in Genolier, Switzerland, explores what is already changing in nuclear medicine and what continues to hold the specialty back.
August 26, 2026
Laim
Suhny Abbara talks AI in scientific publishing
By Claudia Tschabuschnig
Radiology editor-in-chief Dr. Suhny Abbara discusses the need for proactive AI guidance and what excites him most about leading the journal.
August 25, 2026
Suhny
Radiotherapy access could address gynecological cancer disparities
By Amerigo Allegretto
Inadequate radiotherapy infrastructure is one of several drivers of gynecological cancer disparities in LMICs.
August 24, 2026
Radiotherapy 400
Page 1 of 91
Next Page